InvestSMART

EMvision Medical Devices Limited (ASX: EMV) - Announcements

Current share price for EMV : $1.600 0.02 (1.23%)+

ASX company news and announcements for EMvision Medical Devices Limited (EMV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All EMvision Medical Devices Limited (EMV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than EMvision Medical Devices Limited (EMV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for EMvision Medical Devices Limited (EMV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$149 Quarterly Activities/Appendix 4C Cash Flow Report 15 Jul 2026 9:20AM $1.525 $1.600 risen by 4.92%
$149 emu AI methods & insights published in npj Digital Medicine 14 Jul 2026 11:13AM $1.505 $1.600 risen by 6.31%
$149 Aeromedical Study De-Risks Rural & Remote Stroke Use Cases 27 May 2026 8:40AM $1.710 $1.600 fallen by 6.43%
$149 EMVision to Receive $1.17M IGP Grant Instalment 25 May 2026 8:20AM $1.670 $1.600 fallen by 4.19%
$149 Cleansing Notice 12 May 2026 9:47AM $1.890 $1.600 fallen by 15.34%
$149 Application for quotation of securities - EMV 12 May 2026 9:42AM $1.890 $1.600 fallen by 15.34%
$149 emu Pivotal Trial Expansion Adds Acute Ischaemia Detection 11 May 2026 8:27AM $1.908 $1.600 fallen by 16.12%
$149 Change of Director's Interest Notice 24 Apr 2026 9:33AM $1.815 $1.600 fallen by 11.85%
$149 Quarterly Activities/Appendix 4C Cash Flow Report 13 Apr 2026 9:04AM $1.555 $1.600 risen by 2.89%
$149 Notification regarding unquoted securities - EMV 10 Apr 2026 12:30PM $1.565 $1.600 risen by 2.24%
$149 $3.8m R&D Rebate Received & Overseas Finding Approved 16 Mar 2026 8:16AM $1.580 $1.600 risen by 1.27%
$149 Update - S&P DJI March 2026 Rebalance of the All Ordinaries 10 Mar 2026 5:28PM $1.710 $1.600 fallen by 6.43%
$149 S&P DJI Announces March 2026 Quarterly Rebalance 6 Mar 2026 5:05PM $1.660 $1.600 fallen by 3.61%
$149 Half Yearly Presentation 23 Feb 2026 9:31AM $1.750 $1.600 fallen by 8.57%
$149 Half Yearly Report and Accounts 23 Feb 2026 9:20AM $1.750 $1.600 fallen by 8.57%
$149 Notification regarding unquoted securities - EMV 6 Feb 2026 3:27PM $1.760 $1.600 fallen by 9.09%
$149 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jan 2026 8:15AM $1.785 $1.600 fallen by 10.36%
$149 Strong emu Clinical Trial & Program Progress 27 Jan 2026 9:25AM $1.780 $1.600 fallen by 10.11%
$149 Notification of cessation of securities - EMV 2 Jan 2026 2:39PM $1.785 $1.600 fallen by 10.36%
$149 Change of Director's Interest Notice x4 2 Jan 2026 2:32PM $1.785 $1.600 fallen by 10.36%
$149 Notification of cessation of securities - EMV 1 Dec 2025 6:27PM $1.890 $1.600 fallen by 15.34%
$149 First Responder Aeromedical Study Commences 27 Nov 2025 8:23AM $1.850 $1.600 fallen by 13.51%
$149 Notification regarding unquoted securities - EMV 18 Nov 2025 2:41PM $1.800 $1.600 fallen by 11.11%
$149 Change of Director's Interest Notice 18 Nov 2025 2:37PM $1.810 $1.600 fallen by 11.60%
$149 Results of Annual General Meeting 12 Nov 2025 8:21AM $1.860 $1.600 fallen by 13.98%

1 - 25 of 371 results

Page 1 of 15

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.